# Semaglutide Microdosing and Clinical Outcomes

Semaglutide works at tested clinical doses; sustained weight-loss efficacy of weekly maintenance strictly below 0.5 mg remains unestablished in this review.

The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test.

Exact microdose clinical generalization is untested, rather than a demonstrated exact-dose effect with a mapped boundary. Standard-dose contexts span diabetes, non-diabetes, East Asian enrollment, HFpEF, osteoarthritis and CKD, with different endpoints and horizons. These real benefits are retained and cannot be borrowed by sub-0.5 mg claims. Prior-response selection is not a baseline scope restriction.